文献速递妇科

针对高级别非黏液性上皮性卵巢癌患者的通用基因检测倡议及其对癌症治疗的意义

A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
PubMed 文献 · Gynecol Oncol · 2017-06-10

本研究描述了在某机构实施通用基因检测倡议,以提高高级别非黏液性上皮性卵巢、输卵管和原发性腹膜癌(HGOC)患者遗传咨询(GC)和胚系基因检测(GT)的推荐率和接受率至80%以上。回顾性分析2012年9月1日至2015年8月31日连续队列1636例患者,1423例(87.0%)被推荐GC和GT,其中1214例(85.3%)完成GT,217例(17.9%)发现BRCA1或BRCA2突变。结论认为实施倡议后推荐和完成率超过80%,通用检测可识别可能受益于PARP抑制剂治疗的患者。

要点

  • 1636例HGOC患者中1423例(87.0%)被推荐遗传咨询和基因检测。
  • 1214例(85.3%)完成基因检测,217例(17.9%)发现BRCA1/2突变。
  • BRCA阳性患者中167例复发或进展,56例接受PARP抑制剂治疗。

核心结论

  • 实施通用基因检测倡议后,本机构HGOC患者遗传咨询和基因检测的推荐率及完成率超过80%。
  • 对HGOC患者进行通用基因检测是识别可能受益于PARP抑制剂治疗患者的一种策略。

研究设计与样本

  • 回顾性分析连续队列,纳入2012年9月1日至2015年8月31日在妇科肿瘤门诊就诊评估的HGOC患者。
  • 数据来自肿瘤登记处、病历和研究数据库,采用描述性统计评估患者特征及遗传咨询、基因检测和PARP抑制剂使用。
  • 基于Plan-Do-Study-Act循环方法开发了多种临床干预措施,包括医生协调的基因检测、整合遗传咨询和协助遗传咨询转诊。

主要发现

  • 研究期间共1636例患者就诊评估HGOC,其中1423例(87.0%)被推荐接受遗传咨询和基因检测。
  • 被推荐的患者中1214例(85.3%)完成基因检测,217例(17.9%)发现BRCA1或BRCA2突变。
  • BRCA阳性患者中167例为复发或进展性疾病,其中56例接受了PARP抑制剂治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Genetic counseling (GC) and germline genetic testing (GT) for BRCA1 and BRCA2 are considered standard of care for patients with high-grade, non-mucinous epithelial ovarian, fallopian tube, and primary peritoneal cancers (HGOC). We describe a universal genetic testing initiative to increase the rates of recommendation and acceptance of GC and GT to >80% for patients with HGOC at our institution. METHODS: Data from a consecutive cohort of patients seen in our gynecologic oncology clinics between 9/1/2012 and 8/31/2015 for evaluation of HGOC were retrospectively analyzed. Data were abstracted from the tumor registry, medical records, and research databases. Descriptive statistics were used to evaluate patient characteristics and GC, GT, and PARP inhibitor use. Various clinic interventions were developed, influenced by the Plan-Do-Study-Act cycle method, which included physician-coordinated GT, integrated GC, and assisted GC referrals. RESULTS: A cohort of 1636 patients presented to the gynecologic oncology clinics for evaluation of HGOC during our study period, and 1423 (87.0%) were recommended to have GC and GT. Of these, 1214 (85.3%) completed GT and 217 (17.9%) were found to have a BRCA1 or BRCA2 mutation. Among BRCA-positive patients, 167 had recurrent or progressive disease, and 56 of those received PARP inhibitor therapy. CONCLUSIONS: The rates of GC and GT recommendation and completion among patients with HGOC at our institution exceeded 80% following the implementation of a universal genetic testing initiative. Universal genetic testing of patients with HGOC is one strategy to identify those who may benefit from PARP inhibitor therapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bednar EM, Oakley HD, Sun CC, et al. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol. 2017. PMID: 28610746. doi:10.1016/j.ygyno.2017.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。